John Wills, MD
Family Medicine · Upper Marlboro, MDNPI 1457462806
Payments from drug & device makers
Across 270 payments — averaging $22.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Lilly USA, LLC$732
- GSK$380
- Novo Nordisk$377
- AbbVie$328
- Pfizer$300
- plus $2K from 28 others
What the payments were for
- Food & beverage$6,03899%
- Education$751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 68 | $1,585 |
| Lilly USA, LLC | 31 | $732 |
| GSK | 16 | $380 |
| Novo Nordisk | 20 | $377 |
| AbbVie(2 entities) | 11 | $328 |
| Pfizer | 19 | $300 |
| Johnson & Johnson(2 entities) | 9 | $261 |
| Vanda Pharmaceuticals Inc. | 12 | $243 |
| Amgen | 5 | $236 |
| Abbott | 8 | $178 |
| Bayer | 5 | $175 |
| Exact Sciences | 6 | $144 |
| Astellas Pharma US Inc | 5 | $142 |
| Mylan Specialty L.p. | 5 | $125 |
| Sanofi-aventis U.S. LLC | 7 | $121 |
| Boehringer Ingelheim | 5 | $113 |
| Hikma Pharmaceuticals USA | 7 | $103 |
| Kowa Pharmaceuticals America, Inc. | 4 | $84 |
| Merck | 3 | $53 |
| Amarin Pharma, Inc. | 4 | $52 |
| Tris Pharma Inc | 3 | $51 |
| Corium, LLC | 3 | $49 |
| Novartis | 2 | $44 |
| Dexcom, Inc. | 1 | $38 |
| Gilead | 2 | $36 |
| Viatris Specialty LLC | 1 | $31 |
| Atricure, Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Lupin Inc. | 1 | $12 |
| Hologic Sales And Service, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,113 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $44,255 |
| EliquisApixaban | 29 | $30,754 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $19,311 |
| FarxigaDapagliflozin Propanediol | 16 | $19,265 |
| XareltoRivaroxaban | 11 | $17,981 |
| JardianceEmpagliflozin | 15 | $10,515 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $6,988 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,304 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $2,600 |
| Colchicine | 26 | $2,194 |
| Atorvastatin Calcium | 196 | $2,010 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $1,667 |
| Amlodipine Besylate | 212 | $1,667 |
| Tamsulosin Hcl | 98 | $1,639 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $1,621 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $377 | $44,25536 claims |
| AstraZenecaBreztri Aerosphere, Farxiga | $1,585 | $38,57644 claims |
| PfizerEliquis | $300 | $30,75429 claims |
| Johnson & JohnsonXarelto | $261 | $17,98111 claims |
| Boehringer IngelheimJardiance | $113 | $10,51515 claims |
| MerckJanumet | $53 | $2,60011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Upper Marlboro
- Adora OtijiUpper Marlboro$25K
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
- Sharon ChungGlen Burnie$333K
- Michael ObiefuneBaltimore$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.